Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT):

 Article Details
Title: Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence
Dateline: 2020-05-29    DisplayDateline   
Byline: Robert NJ, O'Shaughnessy J, Annavarapu S, Zhou J, Sussell J, Cheng A, Fung A
Publication Title: ASCO  
CTA Link: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e12648
CTA Text: Read More
Filter(s):*
This creates the tags that filter the listing page by specific taxonomies that display to the right of the main content and read more link.
 
 

top